Stephen V. Liu is an Associate Professor and the Director of Thoracic Oncology at Georgetown University and the Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

Aaron E. Lisberg, MD, is a medical oncologist with an emphasis on clinical and translational research in thoracic oncology at the David Geffen School of Medicine at UCLA. He conducts translational research aimed at identifying novel therapeutic approaches for the treatment of thoracic malignancies, with a specific focus on immune-based, cellular, and metabolically targeted therapies and has published extensively.

Dr. Jessica Lin is a medical oncologist specializing in the care of patients with thoracic malignancies. Dr. Lin received her MD from Harvard Medical School. After completing her residency in internal medicine at the Brigham and Women’s Hospital and fellowship in medical oncology at the Dana-Farber/Partners CancerCare program, she joined the faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School. The primary focus of Dr. Lin’s research is to develop novel therapeutic and biomarker strategies for patients with advanced lung cancers. Her translational research efforts are dedicated to the study of resistance mechanisms and exceptional responses to targeted therapies in molecularly defined subsets of lung cancer. Dr. Lin is a member of the International Association for the Study of Lung Cancer, American Association for Cancer Research, and American Society of Clinical Oncology.

Bob Li, MD, PhD, MPH, FRACP, is an Australian medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center, New York, who specializes in early-phase drug development for lung cancers and solid tumors. He is Chief Scientific Officer, MSK Direct, responsible for scientific innovation in MSK’s digital outreach strategy. He is also Co-Director of MSK’s multidisciplinary Thoracic Liquid Biopsy Program which is dedicated to developing the latest biotechnology on circulating biomarkers to transform the care of patients. As MSK’s Physician Ambassador to China and Asia-Pacific, Dr. Li provides administrative leadership in international patient care, research and education programs to advance MSK’s mission abroad with transparency and impact. Through compassionate care and international collaboration, his career is dedicated to winning the global war on cancer and bringing real hope to patients.

Dr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DCDr Levy is a physician scientist who is currently leading global immunotherapy trials. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board.  He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCODr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DCDr Levy is a physician scientist who is currently leading global immunotherapy trials. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board.  He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCO.

Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto.  She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published more than 300 peer-reviewed papers, has held (as principal or co-investigator) over $600 million in peer-reviewed grant funding, and has mentored many oncology trainees that have gone on to leadership roles in oncology around the world. Recently, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award (2019). After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr. Frances Shepherd at the Princess Margaret Hospital in Canada, a Fellowship in Clinical Oncology with Prof. Martin Tattersall at the University of Sydney in Australia, and received her Masters in Medical Science (MMSc) in Clinical Epidemiology at the University of Newcastle, Australia.

Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, and is a member of the IASLC Quality and Value Committee. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board and more. She also served as President of Lung Cancer Canada from 2009 to 2016, and serves on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation.

Dr. Jonathan Lehman is a practicing medical thoracic oncologist at Vanderbilt University Medical Center and the Department of Veterans Affairs in Nashville, TN. Dr. Lehman’s current research focuses on small cell lung carcinoma (SCLC), the most aggressive subtype of lung cancer, and is driven by his clinical experience with Veterans who are disproportionately afflicted by the disease.  SCLC is particularly devastating because most tumors develop metastatic recurrence despite initial response to therapeutic intervention.  Dr. Lehman’s research focuses on rare chemotherapy resistant subpopulations and he has described distinct neuroendocrine survival signaling in SCLC and rare chemotherapy stable subpopulations encovered by a novel single cell mass cytometry panel that can identify the expression of more than 40 individual proteins to cluster subpopulations of cells within a large number of tumor cells.  He is delighted to participate in the Vanderbilt University U54 group focused on characterizing and modeling different subpopulations in Small Cell Lung Cancer.  He is grateful to the NCI, VA, and Department of Defense for continued funding support and his collaborators in the Rudin, Massion, and ECOG and U54 labs.

Jay M. Lee, M.D., is Chief, Division of Thoracic Surgery, Surgical Director of the Thoracic Oncology Program, Surgical Director of the Robert G. Kardashian Center for Esophageal Health, and Associate Professor of Surgery (Tenure Track) at the David Geffen School of Medicine at UCLA. He received his medical degree from UCLA and training in General Surgery at Georgetown and Duke University Medical Centers.  He completed a Thoracic Research Fellowship at Memorial Sloan Kettering Cancer Center and received Thoracic Surgery training at the Brigham and Women’s Hospital and Children’s Hospital Boston at Harvard Medical School. Dr. Lee has published extensively in the field of thoracic oncology and has a funded research laboratory.  His scientific effort has focused on translational trials involving investigator-initiated immunotherapy in human lung cancer and modulation of the immunosuppressive tumor microenvironment. He is the Principal Investigator of the “Combined Gene modified dendritic cell therapy and PD-1 inhibition for lung cancer” trial, which is patented at UCLA.

Dr. Lee is on the Steering/Executive Committee of several neoadjuvant trials in resectable non-small cell lung cancer including LCMC3 (atezolizumab), CANOPY-N (canakinumab and/or pembrolizumab), NAUTIKA1 (alectinib, entrectinib, vemurafenib plus combimetinib, or pralsetinib), and GEOMETRY-N (capmatinib).

Ticiana A. Leal, MD, is faculty in the Division of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin School of Medicine and Public Health. Dr. Leal earned her medical degree from the Federal University of Ceara, Brazil, and completed her residency at University of Chicago Hospitals. She completed her fellowship at University of Wisconsin Hospital and Clinics and the University of Illinois. Dr. Leal is board certified in medical oncology and palliative care medicine. She is a medical oncologist specializing in thoracic malignancies. She is a member of the NCCN NSCLC and mesothelioma/thymic malignancies panels. Her academic appointments include Thoracic Oncology Program Director, and Co-Chair of the Big Ten CRC Thoracic Clinical Trial Working Group. She is a member of the ECOG/ACRIN Thoracic Committee, NRG Oncology Medical Oncology Committee, and member of the IASLC LATAM Latin American Working Group, among many others. She has authored or coauthored numerous peer-reviewed original research articles, book chapters, and posters.

Xiuning Le, MD, PhD is an Assistant Professor in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center.

Dr. Le received her MD from Peking Union Medical College in China and then obtained a PhD in Genetics at Harvard Medical School. Subsequently, she completed her Internal Medicine Residency at the University of Massachusetts Medical Center and the Hematology/Oncology Fellowship at Beth Israel Deaconess Medical Center (BIDMC). After her trainings, she joined MD Anderson as a faculty member in the Department of Thoracic Medical Oncology.

Dr. Le’s clinical focus is on oncogene-driven lung cancers. She applies genomics expertise in her translational work to understand resistance mechanisms to targeted and immunotherapy. Currently, she serves as a PI for multiple trials focusing on EGFR-mutant or MET exon 14 skipping non-small cell lungs. Dr. Le is a recipient of many prestige junior investigator awards, such as stand-up-to-cancer (SU2C)-V scholar, as well as ASCO young investigator award and career development award.